Examples of 'alirocumab' in a sentence
Meaning of "alirocumab"
Alirocumab is a type of medication known as a PCSK9 inhibitor, used to lower levels of 'bad' cholesterol in the blood
Show more definitions
- A human monoclonal antibody used to treat high cholesterol.
How to use "alirocumab" in a sentence
Basic
Advanced
alirocumab
Alirocumab was generally well tolerated in all trials.
Praluent contains the active substance alirocumab.
It is not known whether alirocumab is excreted in human milk.
Two elimination phases were observed for alirocumab.
Effects of alirocumab on other medicinal products.
About the draft guidance for alirocumab.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
It contains the active substance alirocumab.
Alirocumab is expected to degrade to small peptides and individual amino acids.
Serious side effects have been reported with alirocumab.
Alirocumab also helps to reduce other fatty substances from blood in patients with mixed dyslipidaemia.
The active substance is alirocumab.
Alirocumab was generally well tolerated in the nine ODYSSEY trials.
The following adverse reactions were reported in patients treated with alirocumab in pooled controlled studies.
Alirocumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.
See also
Regeneron and Sanofi were allowed to continue marketing alirocumab during the appeals process.
Alirocumab is a human monoclonal antibody of the IgG1 isotype.
Detailed results from four pivotal Phase III alirocumab trials presented at the ESC congress.
Alirocumab is generally well-tolerated with an acceptable safety profile.
So far, clinical studies of alirocumab suggest it is similar in effectiveness to evolocumab.
Specific metabolism studies were not conducted, because alirocumab is a protein.
The common side effects with alirocumab were itching, redness, and swelling at the injection site.
Based on a population pharmacokinetic analysis, gender has no impact on alirocumab pharmacokinetics.
They either received alirocumab by self-injection under the skin every two weeks or placebo injections.
Based on a population pharmacokinetic analysis, race had no impact on alirocumab pharmacokinetics.
Alirocumab is in the class of drugs called PCSK9 antibodies.
This leads to the increased target-mediated clearance and reduced systemic exposure of alirocumab.
Alirocumab is one of the most promising projects in Sanofi 's pipeline.
Excretion, Two elimination phases were observed for alirocumab.
The long-term consequences of continuing alirocumab treatment in the presence of ADA are unknown.
Gender, Based on a population pharmacokinetic analysis, gender was found not to significantly influence alirocumab pharmacokinetics.
Free PCSK9 concentrations returned to baseline when alirocumab concentrations decreased below the limit of quantitation.
Alirocumab is an investigational monoclonal antibody targeting PCSK9.
There are currently two PCSK9 inhibitors on the market, alirocumab and evolocumab.
Alirocumab works by inhibiting the PCSK9 protein.
Table 1 - Adverse Reactions reported in patients treated with alirocumab in pooled controlled studies.
The price of alirocumab was determined based in part on making apheresis no longer necessary . [ 2 ].
ODYSSEY is the global Phase 3 trial program for investigational compound alirocumab.
Approximately 80 percent of patients in the alirocumab group remained on the initial 75 mg alirocumab dose.
Praluent 75 mg solution for injection in pre-filled syringe alirocumab.
In this study, alirocumab monotherapy reduced “ bad ” cholesterol three times more than ezetimibe.
ODYSSEY LONG TERM -- long term results underscore efficacy and safety of alirocumab for lowering cholesterol.
Alirocumab will be available in a single-dose pre-filled pen that patients self-administer.
EBM, Can you give us your update on alirocumab in cholesterol treatment?
Alirocumab has been designed to attach to a protein called ‘ PCSK9.
There is two PCSK9 inhibitors on the market, alirocumab and evolocumab.
The filing of alirocumab in hypercholesterolemia in EU is expected in the fourth quarter of 2014.
Table 1 - Adverse Reactions reported in patients treated with alirocumab in controlled studies and post-marketing use.
Alirocumab is an investigational monoclonal antibody targeting PCSK9 proprotein convertase subtilisin / kexin type 9.
Praluent 75 mg injection alirocumab Subcutaneous use.
